To date,the overall response rate of PD-1 blockade remains unsatisfactory,partially due to limited understanding of tumor immune microenvironment(TIME).B-cell lymphoma 9(BCL9),a key transcription co-activator of the W...To date,the overall response rate of PD-1 blockade remains unsatisfactory,partially due to limited understanding of tumor immune microenvironment(TIME).B-cell lymphoma 9(BCL9),a key transcription co-activator of the Wnt pathway,is highly expressed in cancers.By genetic depletion and pharmacological inhibition of BCL9 in tumors,we found that BCL9 suppression reduced tumor growth.展开更多
基金This study was partially supported by grants from National Natural Science Foundation of China(81872895 and 82073881 to D.Z.,81872915,82073904,and 82011530150 to M.-W.W.)Shanghai Municipal Education Commission(Shanghai Top-Level University Capacity Building Program DGF817029-04 to M.-W.W.)+1 种基金Shanghai Science and Technology Commission(18ZR1403900,20430713600,and 18JC1413800 to D.Z.)Fudan-SIMM Joint Research Fund(FU-SIMM20181010 to D.Z.and D.Y.).
文摘To date,the overall response rate of PD-1 blockade remains unsatisfactory,partially due to limited understanding of tumor immune microenvironment(TIME).B-cell lymphoma 9(BCL9),a key transcription co-activator of the Wnt pathway,is highly expressed in cancers.By genetic depletion and pharmacological inhibition of BCL9 in tumors,we found that BCL9 suppression reduced tumor growth.
